A pilot clinical study investigating the synergism of cryoablation and pre-operative single-dose ipilimumab (anti-CTLA-4) in early-stage breast cancer patients demonstrated the safety and, importantly, the favorable systemic immunologic and intra-tumoral effects of this combination. Here, CTLA4 is linked to breast carcinoma.